Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9627687 | 0.79 | TAAR1 (0.62) | TAAR1MAPTSMN1; SMN2ALDH1A1INPP5D | |
| SCHEMBL5758263 | 0.78 | TAAR1 (0.53) | TAAR1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL7583720 | 0.76 | MAPT (0.42) | TAAR1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL8415982 | 0.76 | MAPT (0.42) | TAAR1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL7689039 | 0.76 | MAPT (0.61) | TAAR1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL29708126 | 0.76 | MAPT (0.61) | TAAR1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL28695196 | 0.76 | MAPT (0.54) | TAAR1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL28695201 | 0.76 | MAPT (0.54) | TAAR1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL7583001 | 0.76 | ALDH1A1 (0.41) | TAAR1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL7584899 | 0.75 | NPC1 (0.40) | TAAR1MAPTSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670307-B2 | Such as 2-(2,6-difluorophenyl)-4-(4-(2-ethoxypyridin-5-yl) phenyl)oxazoline; for administration to livestock | HOECHST SCHERING AGREVO GMBH (DE) | 2003-12-30 | — | — | US | disclosed |
| EP-1087967-B1 | 1,3-OXAZOLINE AND 1,3-THIAZOLINE DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS PESTICIDES | BAYER CROPSCIENCE GMBH (DE) | 2003-10-22 | — | — | EP | disclosed |
| US-20020068828-A1 | 1,3-oxazoline and 1,3-thiazoline derivatives, their preparation, and their use as pesticides | BAYER CROPSCIENCE AG (DE) | 2002-06-06 | — | — | US | disclosed |
| CN-1305476-A | 1,3-oxazoline and 1,3-thiazoline derivatives, method for producing the same and their use as pesticides | AVENTIS CORP SCIENCE GMBH (DE) | 2001-07-25 | — | — | CN | disclosed |
| US-6265350-B1 | CONTROLLING HARMFUL FUNGI, INSECTS, ACARINA, MOLLUSKS AND NEMATODES | HOECHST SCHERING AGREVO GMBH (DE) | 2001-07-24 | — | — | US | disclosed |
| EP-1087967-A1 | 1,3-OXAZOLINE AND 1,3-THIAZOLINE DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS PESTICIDES | Aventis CropScience GmbH (DE) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065901-A1 | 1,3-OXAZOLINE AND 1,3-THIAZOLINE DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS PESTICIDES | AVENTIS CROPSCIENCE GMBH (DE) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068828-A1 | 1,3-oxazoline and 1,3-thiazoline derivatives, their preparation, and their use as pesticides | MT-CO1, OXA1L, MT-CO3 | TAAR1 628/4885MAPT 3869/4885SMN1; SMN2 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.